Greater drop in LDL seen with atorvastatin plus PCSK9 antibody

November 2, 2012
Greater drop in LDL seen with atorvastatin + PCSK9 antibody
Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein cholesterol levels compared with atorvastatin alone, according to a study published online Oct. 31 in the New England Journal of Medicine.

(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels compared with atorvastatin alone, according to a study published online Oct. 31 in the New England Journal of Medicine.

Eli M. Roth, M.D., from the Sterling Research Group in Cincinnati, and colleagues performed a phase 2 trial involving 92 patients with ≥100 mg/dL after at least seven weeks of treatment with 10 mg . Participants were randomized to three groups to receive eight weeks of 10 or 80 mg daily atorvastatin, plus SAR236553 once every two weeks, or eight weeks of 80 mg atorvastatin with placebo once every two weeks.

The researchers found that there was a significantly greater least-squares mean percent reduction from baseline in LDL cholesterol for treatment with 80 mg atorvastatin plus SAR236553 (73.2 ± 3.5) compared with 10 mg atorvastatin plus SAR236553 (66.2 ± 3.5) or atorvastatin plus placebo (17.3 ± 3.5). All patients who received SAR236553 attained an LDL <100 mg/dL, compared with 52 percent of those receiving 80 mg atorvastatin plus placebo. At least 90 percent of patients who received SAR236553 attained LDL levels <70 mg/dL, compared with 17 percent of those who received 80 mg atorvastatin plus placebo.

"In a involving patients with primary hypercholesterolemia, adding SAR236553 to either 10 mg of atorvastatin or 80 mg of atorvastatin resulted in a significantly greater reduction in LDL cholesterol than that attained with 80 mg of atorvastatin alone," the authors write.

The study was funded by Sanofi and Regeneron Pharmaceuticals, both of which manufacture SAR236553; several authors are employed by Sanofi.

Explore further: Antibody injection lowers LDL, adding to effectiveness of statin therapy

More information: Abstract
Full Text

Related Stories

Antibody injection lowers LDL, adding to effectiveness of statin therapy

March 26, 2012
A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering ...

Two statin drugs similarly effective in reversing coronary heart disease

November 15, 2011
Maximum doses of Crestor (rosuvastatin) or Lipitor (atorvastatin) are similarly effective in reversing the buildup of cholesterol plaques in the coronary artery walls (atherosclerosis) after 24 months of treatment, according ...

US approves India's Ranbaxy to make generic Lipitor

December 1, 2011
Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.

Statin alternative looks promising in early trials

March 22, 2012
(HealthDay) -- Administration of REGN727, a monoclonal antibody to proprotein convertase subtilisin/kexin 9 (PCSK9), significantly reduces low-density lipoprotein (LDL) cholesterol levels, according to the results of three ...

Recommended for you

Study finds walnuts may promote health by changing gut bacteria

July 28, 2017
Research led by Lauri Byerley, PhD, RD, Research Associate Professor of Physiology at LSU Health New Orleans School of Medicine, has found that walnuts in the diet change the makeup of bacteria in the gut, which suggests ...

Green tea ingredient may ameliorate memory impairment, brain insulin resistance, and obesity

July 28, 2017
A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active component in green tea, could alleviate high-fat and high-fructose ...

Manipulating a type of brain cell gets weight loss results in mice

July 28, 2017
A new study has found something remarkable: the activation of a particular type of immune cell in the brain can, on its own, lead to obesity in mice. This striking result provides the strongest demonstration yet that brain ...

Team finds link between backup immune defense, mutation seen in Crohn's disease

July 27, 2017
Genes that regulate a cellular recycling system called autophagy are commonly mutated in Crohn's disease patients, though the link between biological housekeeping and inflammatory bowel disease remained a mystery. Now, researchers ...

Study finds harmful protein on acid triggers a life-threatening disease

July 27, 2017
Using an array of modern biochemical and structural biology techniques, researchers from Boston University School of Medicine (BUSM) have begun to unravel the mystery of how acidity influences a small protein called serum ...

CRISPR sheds light on rare pediatric bone marrow failure syndrome

July 27, 2017
Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.